Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
46.5 USD | -3.85% | +7.64% | +26.15% |
May. 03 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
May. 03 | Sector Update: Health Care Stocks Mixed in Afternoon Trading | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+26.15% | 2.82B | C- | ||
-1.18% | 91.42B | A- | ||
+3.16% | 41.08B | A- | ||
-11.10% | 34.26B | B- | ||
+53.99% | 25.27B | A | ||
-9.41% | 12.81B | B- | ||
-12.25% | 11.6B | D+ | ||
-44.00% | 11.42B | B | ||
+5.77% | 9.16B | B+ | ||
-6.90% | 8.22B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TWST Stock
- Ratings Twist Bioscience Corporation